Christopher Alan Riley, LCSW | |
1005 S Meridian St, Lebanon, IN 46052-2784 | |
(765) 482-7421 | |
(765) 482-7462 |
Full Name | Christopher Alan Riley |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 1005 S Meridian St, Lebanon, Indiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346347721 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 35001034A (Indiana) | Secondary |
1041C0700X | Social Worker - Clinical | 34003117A (Indiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Christopher Alan Riley, LCSW 947 Voyager Way, Lafayette, IN 47909-8033 Ph: (765) 572-2230 | Christopher Alan Riley, LCSW 1005 S Meridian St, Lebanon, IN 46052-2784 Ph: (765) 482-7421 |
News Archive
Every night while sleeping, we cycle between two very different states of sleep. Upon falling asleep, we enter non-rapid eye movement sleep where our breathing is slow and regular and movement of our limbs or eyes are minimal.
Children who live in more walkable neighborhoods have a smaller waist measurement and a lower BMI (body mass index). Those are the findings of a Montreal research team led by INRS professor Tracie A. Barnett. According to the results of the study published in Preventive Medicine by Adrian Ghenadenik (lead author) with Professor Barnett (senior contributing author), urban design is a factor in the development of childhood obesity.
With the aid of X-ray crystallography, researchers at the University of Michigan have revealed the structures of two closely related enzymes that play essential roles in the body's ability to metabolize excess lipids, including cholesterol.
GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
› Verified 4 days ago